Literature DB >> 21561350

The tumor lysis syndrome.

Scott C Howard1, Deborah P Jones, Ching-Hon Pui.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21561350      PMCID： PMC3437249          DOI： 10.1056/NEJMra0904569

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  50 in total

1.  A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults.

Authors:  Miriam Giraldez; Katarzyna Puto
Journal:  Eur J Haematol       Date:  2010-04-12       Impact factor: 2.997

Review 2.  Genetic disorders of renal phosphate transport.

Authors:  Dominique Prié; Gérard Friedlander
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.

Authors:  C H Pui; H H Mahmoud; J M Wiley; G M Woods; G Leverger; B Camitta; C Hastings; S M Blaney; M V Relling; G H Reaman
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

4.  Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose.

Authors:  Jean-Pierre Gutzwiller; Daniel Schneditz; Andreas R Huber; Christian Schindler; Felix Gutzwiller; Carlos E Zehnder
Journal:  Nephrol Dial Transplant       Date:  2002-06       Impact factor: 5.992

5.  Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration.

Authors:  H K Tan; R Bellomo; D A M'Pis; C Ronco
Journal:  Int J Artif Organs       Date:  2001-04       Impact factor: 1.595

6.  Effects of urinary macromolecules on hydroxyapatite crystal formation.

Authors:  Ann M Beshensky; Jeffrey A Wesson; Elaine M Worcester; Elena J Sorokina; Carl J Snyder; Jack G Kleinman
Journal:  J Am Soc Nephrol       Date:  2001-10       Impact factor: 10.121

7.  A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.

Authors:  S C Goldman; J S Holcenberg; J Z Finklestein; R Hutchinson; S Kreissman; F L Johnson; C Tou; E Harvey; E Morris; M S Cairo
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

8.  Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.

Authors:  C H Pui; S Jeha; D Irwin; B Camitta
Journal:  Leukemia       Date:  2001-10       Impact factor: 11.528

Review 9.  Tumour lysis syndrome: new therapeutic strategies and classification.

Authors:  Mitchell S Cairo; Michael Bishop
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

10.  Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome.

Authors:  Tony H Truong; Joseph Beyene; Johann Hitzler; Oussama Abla; Anne Marie Maloney; Sheila Weitzman; Lillian Sung
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860
View more
  207 in total

1.  Pseudohyperkalemia without reported haemolysis in a patient with chronic lymphocytic leukaemia.

Authors:  James S Chan; Stacy L Baker; Aaron W Bernard
Journal:  BMJ Case Rep       Date:  2012-01-10

Review 2.  Spontaneous tumour lysis syndrome.

Authors:  Natasha Kekre; Bojana Djordjevic; Claire Touchie
Journal:  CMAJ       Date:  2012-04-10       Impact factor: 8.262

3.  The tumor lysis syndrome.

Authors:  Jason M Elinoff; Rachel B Salit; Hans C Ackerman
Journal:  N Engl J Med       Date:  2011-08-11       Impact factor: 91.245

4.  Tumor Lysis Syndrome in an Unusual Metastatic Pancreatic Neuroendocrine Tumor with Ectopic ACTH Secretion.

Authors:  Michael Shusterman; Noah A Bloomgarden; Susan T Sotardi; Aditi Shastri
Journal:  J Gastrointest Cancer       Date:  2016-12

Review 5.  Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.

Authors:  Bilal Farooqi; Josh Simmons; Zhonglin Hao
Journal:  J Gastrointest Cancer       Date:  2015-09

6.  Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Authors:  John F Seymour; Shuo Ma; Danielle M Brander; Michael Y Choi; Jacqueline Barrientos; Matthew S Davids; Mary Ann Anderson; Anne W Beaven; Steven T Rosen; Constantine S Tam; Betty Prine; Suresh K Agarwal; Wijith Munasinghe; Ming Zhu; L Leanne Lash; Monali Desai; Elisa Cerri; Maria Verdugo; Su Young Kim; Rod A Humerickhouse; Gary B Gordon; Thomas J Kipps; Andrew W Roberts
Journal:  Lancet Oncol       Date:  2017-01-13       Impact factor: 41.316

7.  Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.

Authors:  Lianwen Zhang; Michael B Steele; Nathan Jenks; Jacquelyn Grell; Marshall Behrens; Rebecca Nace; Shruthi Naik; Mark J Federspiel; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2016-09-26       Impact factor: 11.454

Review 8.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

9.  Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.

Authors:  Helena S Gouveia; Sílvia O Lopes; Ana Luísa Faria
Journal:  BMJ Case Rep       Date:  2018-03-15

Review 10.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.